Expression of tumor Ki-67, a cellular biomarker for proliferative activity, has been shown correlate with overall survival (OS) and progression-free survival (PFS) in PCNSL patients [15–17]. This evidence concerns the gene MKI67 and primary central nervous system lymphoma.